May 12, 2021
Article
In addition to comorbidity frequency, the researchers also studied the comparison of comorbidities between men and women with migraine.
The founder and chief scientific officer of Neurolutions discussed how the company’s newly approved chronic stroke rehabilitation system will provide expanded benefits to post-stroke patients.
Video
The director at AbbVie discussed the timeline for when a regulatory decision may come for migraine treatment atogepant, and whether additional trials are necessary.
Clive Ballard, MD, the executive dean at the University of Exeter Medical School, discussed the safety and efficacy profile of pimavanserin (Nuplazid; Acadia Pharmaceuticals).
A poster presentation at the American Psychiatric Association Virtual Meeting suggests that late-life depression might predict self-reported cognitive complaints.
May 11, 2021
The clinical research director at the UCSF Multiple Sclerosis Center shared some of the takeaways from his research for the clinical community of specialists treating patients with NMOSD.
The partnership combines Capsigen’s vector engineering with Biogen’s drug pipeline, seeking to develop gene therapies for neuromuscular and central nervous system disorders.
The associate professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University discussed the potential of a data-driven approach to classifying patients with MS.
Sleep depth was observed to be an independent predictor of heart rate change following seizure for patients with epilepsy.
The chief of neurology at Ascension Saint Agnes discussed the interventions her team implemented to improve patient-specific stroke discharge instructions.
